On the stock market since 1996, it operates in the world of health and science. It has 258 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 239% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 70% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 576% a year on average.
Sales run at $183.9M a year. A small number, but proof the product has real buyers.
There is $359.8M in the vault; even if every debt were paid off, $108.2M would remain.
A loss of $85.8M against $183.9M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 38/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 47/100.
On our five-subject report card, GERN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GERN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (47/100) says the stock isn’t cheap.